Skip to main content
BLCMinactive

BELLICUM PHARMACEUTICALS, INC

Biopharma developer (SEC filing verified)·Phase 1·CEO: Richard A. Fair
Oncology

BLCM evidence brief

What we can confirm

BioSniper Score:
5.3 / 10
Lead Asset:
bpx-601 (Phase 1/Phase 2)

What it means

The company data is ready for cross-source review; unsupported conclusions remain unknown.

What to watch

BioSniper Score: 5.3 / 10 · Lead Asset: bpx-601 (Phase 1/Phase 2)
BioSniper AIPage evidence connected

Prepared research question

What matters most for BLCM—catalysts, financial risk and supporting evidence?

Run cited research

Traceable citations · Unknowns marked

5.3/10

BioSniper Score

Based on 2 of 6 signals

Limited data coverage

Market Cap

—

Cash Runway

—

Lead Asset

bpx-601 (Phase 1/Phase 2)

Next Catalyst

—

Tracking 2 pipeline candidates for BELLICUM PHARMACEUTICALS, INC.

Run BELLICUM PHARMACEUTICALS, INC through your own thesis

Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.

Your protocol can:

  • Turn available BELLICUM PHARMACEUTICALS, INC facts into screen rules or deeper checks
  • Show cited findings, blockers, and unresolved evidence together
  • Save the logic and rerun it as the company evidence changes
Run a thesis on this company — freeRun a thesis on this company

Score breakdownBased on 2 of 6 signals · derived from public data

Cash RunwayN/A

Cash runway data unavailable

Financial HealthN/A

Financial health data unavailable

Pipeline Maturity6.0

Lead: Phase 1/Phase 2

Pipeline Breadth4.6

2 candidates

Catalyst MomentumN/A

No upcoming catalysts tracked

Insider SignalN/A

No insider transactions in the last 180 days

Pipeline

Run my thesis on this company

Frequently asked questions

What is BELLICUM PHARMACEUTICALS, INC's lead drug candidate?

BELLICUM PHARMACEUTICALS, INC's most advanced tracked candidate is bpx-601 (Phase 1/Phase 2) for metastatic castration-resistant prostate cancer and metastatic pancreatic cancer expressing PSCA.

Who is the CEO of BELLICUM PHARMACEUTICALS, INC?

Richard A. Fair is the chief executive officer of BELLICUM PHARMACEUTICALS, INC (BLCM).

What therapeutic areas does BELLICUM PHARMACEUTICALS, INC focus on?

BELLICUM PHARMACEUTICALS, INC develops therapies across Oncology.

923 companies304,844 SEC filings22,644 clinical trials100% citation-verification pass rate (7d)How we verify →

The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.